Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
BFORCURE is active in the Biotechnology & Pharmaceuticals technology area with 2 pending office actions. These actions are distributed across 2 distinct examiners, but they are both contained within 1 distinct art unit. This suggests that while the technical focus is consistent, the company is dealing with different individual perspectives during the examination process for its current filings.
The busiest examiner for the portfolio is WILDER, CYNTHIA B, who is currently managing 1 pending office action. Since there are 2 pending actions in total and 2 distinct examiners, the workload is split evenly. This requires practitioners to manage two separate prosecution tracks even though they are both within the same art unit. The lack of examiner concentration means that no single individual's preferences will dictate the entire portfolio's outcome.
The concentration in 1 distinct art unit within the Biotechnology & Pharmaceuticals area may provide some consistency in the broad legal standards applied to the applications. However, the presence of 2 distinct examiners means that the specific hurdles for each application will be determined by different individuals. Practitioners should tailor their responses to the unique requirements of each examiner while maintaining a cohesive technical narrative across the 2 pending office actions.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WILDER, CYNTHIA B | 1 | 71.0% | +26.6% |
| KIM, YOUNG J | 1 | 64.8% | +18.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18722223 | COMPOSITION AND METHOD FOR AMPLIFYING NUCLEIC ACID SEQUENCES | WILDER, CYNTHIA B | — |
| 18293180 | DEVICE AND METHOD FOR MULTIPLEXED DETECTION OF NUCLEIC ACID SEQUENCES | KIM, YOUNG J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18722223 | COMPOSITION AND METHOD FOR AMPLIFYING NUCLEIC ACID SEQUENCES | WILDER, CYNTHIA B | — |
| 18293180 | DEVICE AND METHOD FOR MULTIPLEXED DETECTION OF NUCLEIC ACID SEQUENCES | KIM, YOUNG J | — |
| Art Unit | Apps |
|---|---|
| 1681 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18722223 | COMPOSITION AND METHOD FOR AMPLIFYING NUCLEIC ACID SEQUENCES | WILDER, CYNTHIA B | — | §103§112 | Non-Final OA | — | Pending | Jun 20, 2024 |
| 18293180 | DEVICE AND METHOD FOR MULTIPLEXED DETECTION OF NUCLEIC ACID SEQUENCES | KIM, YOUNG J | 1681 | §103§112 | Non-Final OA | — | Pending | Jan 29, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial